Samsung Bioepis Settles Patent Disputes with AbbVie, Clearing the Way for the Commercialization of SB5 (Adalimumab) in All Approved Markets Worldwide
Samsung Bioepis Co., Ltd. today announced that it has signed a licensing agreement with AbbVie Inc., settling all pending patent litigation between the two companies and clearing the way for the worldwide commercialization of Samsung Bioepis’ SB5, a biosimilar referencing Humira® i (adalimumab), in all approved markets worldwide. Under the terms of the agreement, SB5 may be launched in Europe from October 16, 2018 onwards and, if approved, in the United States (US) from June 30, 2023 onwards.
SB5 has been granted marketing authorization by the European Commission (EC) as IMRALDI®, and will be commercialized in Europe by Biogen. In the US, SB5 has not yet received regulatory approval.
“We welcome this agreement which clears the way for SB5 in approved markets across the world. The earliest impact of this agreement will likely be seen in Europe, where SB5 has already been approved and is expected to become our third TNF inhibitor available in the region,” said Jaywoo Kim, Senior Vice President and Head of the Commercial Division at Samsung Bioepis. “Through relentless process innovation and an uncompromising commitment to quality, we remain dedicated to advancing one of the industry's strongest biosimilar pipelines, so that more patients and healthcare systems across the world may benefit from biosimilars.”
About Samsung Bioepis Co., Ltd.
Established in 2012, Samsung Bioepis is a biopharmaceutical company committed to realizing healthcare that is accessible to everyone. Through innovations in product development and a firm commitment to quality, Samsung Bioepis aims to become the world's leading biopharmaceutical company. Samsung Bioepis continues to advance a broad pipeline of biosimilar candidates that includes six late-stage candidates that cover the therapeutic areas of immunology, oncology and diabetes. Samsung Bioepis is a joint venture between Samsung BioLogics and Biogen. For more information, please visit: www.samsungbioepis.com.
i Humira ® is a registered trademark of AbbVie Inc.
Samsung Bioepis Co., Ltd.
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Tilaa tiedotteet sähköpostiisi
Haluatko tietää asioista ensimmäisten joukossa? Kun tilaat mediatiedotteemme, saat ne sähköpostiisi välittömästi julkaisuhetkellä. Tilauksen voit halutessasi perua milloin tahansa.
Lue lisää julkaisijalta Business Wire
Andersen Global Expands UK Locations23.5.2019 16:30:00 EEST | Tiedote
Claritas Tax Limited, a Birmingham, United Kingdom-based collaborating firm of Andersen Global, has opened a new office location in Deansgate, Manchester city center. This means that Andersen Global now has a presence in six locations in the UK through its member firms and collaborating firms. “Now more than ever, it’s important that businesses have easy access to quality advice in the UK’s dynamic political and business environment. The addition of another location in the region adds to our existing capabilities and will allow us to continue providing best-in-class service,” said Mark Vorsatz, Andersen Global Chairman and CEO of Andersen Tax LLC. Founded in 2012, Claritas Tax Limited has a list of clientele from entrepreneurial, privately owned, venture capital, and private equity owned businesses, listed companies and stakeholders. Claritas provides a broad range of tax consulting services, including all aspects of M&A and transactional taxes, R&D and Intellectual Property claims, sh
Mindbreeze Receives Attestation in Accordance with BSI Cloud Requirements23.5.2019 16:11:00 EEST | Tiedote
Mindbreeze receives attestation for its Mindbreeze InSpire SaaS service according to the specifications of the C5 catalogue of requirements (Cloud Computing Compliance Controls Catalogue, abbreviated C5), published by the German Federal Office for Information Security (BSI). The Mindbreeze InSpire SaaS service is professionally operated in Mindbreeze data centers on behalf of the customers. The attestation was issued by KPMG Alpen-Treuhand GmbH Wirtschaftsprüfungs- und Steuerberatungsgesellschaft. “The number of cloud services in the field of data analysis is growing steadily. This makes it all the more essential for customers to take a closer look at the choice of suppliers. C5 provides the regulatorily defined IT security level, which is comparable to the IT basic protection level that is increased by cloud controls,” explains Klaus Schatz, Managing Director of KPMG Advisory GmbH. C5 attestation (ISAE 3000 Report Type 2) is a recognized and authoritative verification for all customer
Bacardi Limited Announces 5th Annual Good Spirited Awards for Employee-Led Global Environmental Sustainability Programs23.5.2019 15:15:00 EEST | Tiedote
In continuation of its ongoing sustainability efforts, Bacardi Limited is proud to announce the recipients of its 5th annual Bacardi Limited Good Spirited Awards. Launched in 2014, the awards recognize the employees, teams and facilities across the company’s global network that developed the best environmental programs across five different categories: Production Facility, Brand Innovation, Sustainable Office, Green Champions or Partnerships. This year’s winners instituted programs to shift to renewable energy, reduce water use and waste, increase recycling efforts and amplify the Bacardi Limited No Straws campaign to decrease the amount of single-use plastic straws by one billion over the next two years. The awards acknowledge activities that took place between April 1, 2018 and March 31, 2019. “Bacardi Limited’s Good Spirited Awards truly underscore the company’s foundation and support of global environmental sustainability efforts at our facilities and in our communities,” says Rick
Teridion Announces Deep Integration with Cisco Meraki MX Security and SD-WAN Appliances to Deliver New High Performance Internet Service23.5.2019 15:00:00 EEST | Tiedote
Teridion, the company delivering the only global public cloud-based WAN service, today announced its deep integration with Cisco Meraki MX Security and SD-WAN appliances. The combined solution is a bold new approach to branch networking, delivering the industry-leading Auto VPN and SD-WAN capabilities of Cisco Meraki’s MX appliances with Teridion’s high throughput and low latency public cloud-based WAN service. For the first time, enterprises can take advantage of a WAN solution that has visibility and control of first, middle, and last mile of the Internet and extends SD-WAN and WAN acceleration beyond enterprise sites to include SaaS applications and enterprise cloud workloads across multiple public cloud providers. Today’s announcement highlights the new, seamless network level integration between Teridion’s high performance cloud WAN service and Cisco Meraki’s easy-to-use Auto VPN routing and high availability capabilities. Enterprise of all sizes can expect real-time applications
C.H. Robinson Acquires Dema Service S.p.A. to Expand Global Presence23.5.2019 14:00:00 EEST | Tiedote
C.H. Robinson (NASDAQ: CHRW) continues to expand its global footprint with its announcement of the acquisition of Dema Service S.p.A. (Dema Service) on May 22, 2019. Dema Service is a leading provider of European road transportation based in Italy. “The acquisition of Dema Service is an exciting milestone for C.H. Robinson and will strengthen our existing footprint in Italy, one of the largest road transportation markets in Europe,” said Jeroen Eijsink, President of Europe for C.H. Robinson. “We are eager to work with Dema Service’s customers to offer our full suite of logistics services to help improve their supply chains.” This is the second European acquisition for C.H. Robinson in 2019. The company recently acquired the freight forwarding group Space Cargo, which expanded C.H. Robinson’s presence in Spain and Columbia. Dema Service is a privately-owned logistics company providing road transportation services across Europe. Headquartered in Pescara, Italy, Dema Service has approxima
Rapid Multiplexing with Opal® Research Kits Now Available on LabSat™ Platform23.5.2019 13:30:00 EEST | Tiedote
Lunaphore Technologies S.A., a Swiss medtech firm developing innovative next-generation equipment for cancer research and tissue diagnostics, announces a new rapid multiplexing application for its LabSat™ Research instrument. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190523005082/en/ FFPE IF of tonsil, 6-plex + DAPI. Total staining time: 4h12 (with Opal® 7-Color Manual IHC Kit) (Photo: Business Wire) Following the signature of a co-marketing agreement between Lunaphore Technologies S.A. and Akoya Biosciences, Inc.; Lunaphore will start providing multiplexing protocols using Akoya’s Opal® immunoassay kits for its staining platform LabSat™ Research, Lunaphore’s first solution to reach the market. LabSat™ is shown to perform rapid tests on tissue samples under 2.5 hours for a 3-plex plus counterstaining with the Opal® 4-Color Manual IHC Kit; and under 4.5 hours for a 6-plex plus counterstaining with the Opal® 7-Color Manua
Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.Tutustu uutishuoneeseemme